Quick Answer
Bioventus Inc. reported Gross Profit of $388.16 million for the year ending 2025.
- Bioventus Inc. showed a decrease of 0.0% in Gross Profit from 2024 to 2025.
- This data is from Bioventus Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $57.24 million | Q2 2020: $40.35 million | Q3 2020: $62.46 million | Q1 2021: $59.56 million | Q2 2021: $76.31 million | Q3 2021: $79.07 million | Q1 2022: $75.70 million | Q2 2022: $96.65 million | Q3 2022: $84.54 million | Q1 2023: $73.92 million | Q2 2023: $89.12 million | Q3 2023: $78.85 million | Q1 2024: $88.38 million | Q2 2024: $103.64 million | Q3 2024: $93.55 million | Q1 2025: $83.06 million | Q2 2025: $102.09 million | Q3 2025: $94.23 million.
- Over the full 7 years of available data (2019 to 2025), Bioventus Inc.'s Gross Profit has grown by 55.8%.
- Historical annual values: Fiscal year 2025: $388.16 million | Fiscal year 2024: $388.23 million | Fiscal year 2023: $328.19 million | Fiscal year 2022: $331.08 million | Fiscal year 2021: $302.71 million | Fiscal year 2020: $233.52 million | Fiscal year 2019: $249.21 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: